Taxane‐based chemoirradiation for organ preservation with locally advanced head and neck cancer: Results of a phase II multi‐institutional trial

Abstract

There were no significant differences in relapse-free survival or organ preservation rates between concurrent regimens. Platinum and paclitaxel-based CCR is feasible after ICT and provides a high rate of organ preservation. Substitution of concurrent cisplatin to weekly carboplatin with paclitaxel and radiation has an improved toxicity profile. The ease of administration and low toxicity make this a regimen that is practical for use in the community setting.

Treatment of Base of Tongue Cancer With Paclitaxel, Ifosfamide, and Cisplatinum Induction Chemotherapy Followed by Chemoradiotherapy

“…Although follow‐up is brief, this CR has been sustained, with 13 patients being disease free for over 2 years after completing therapy. Similar protocols of induction chemotherapy followed by concurrent chemoradiation in patients with head and neck cancer have shown overall response rates ranging from 80% to 90% with CR rates ranging from 40% to 90% 3,7 . Although these trials have larger numbers and are not base of tongue specific, the results provided here are similar with an overall response rate and CR rate of 94%.…”

“…Similar protocols of induction chemotherapy followed by concurrent chemoradiation in patients with head and neck cancer have shown overall response rates ranging from 80% to 90% with CR rates ranging from 40% to 90%. 3,7 Although these trials have larger numbers and are not base of tongue specific, the results provided here are similar with an overall response rate and CR rate of 94%. Many studies have similar diseasefree survival and OS rates.…”

Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel

“…Paclitaxel -representative of the second generation chemotherapy -has been used in SCCHN single-agent [7,14] or platinum-based radiochemotherapy protocols [2,6,8,15,22,25]. Current treatment strategies often use hyperfractionated or hyperfractionated-accelerated radiotherapy protocols to enhance efficacy.…”

Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study)

“…This percentage is very much higher than that of other studies and, probably, would have had a negative impact on the response rate and OS. Secondly, the concurrent schedule differs signifi cantly from trials evaluating concurrent taxanes and radiotherapy [11,12,14,[21][22][23][24]. For example, Matsumoto et al published the results of a study in 25 patients with advanced H&N treated with weekly docetaxel (10 mg/m 2 ) and hyperfractionation radiotherapy (72 Gy at 1.2 Gy twice daily).…”